September 14, 2009. The National Research Center for Women & Families submits the following comments regarding the laser-assisted in situ keratomileusis (LASIK) and the post market experience associated with the use of LASIK devices.
Read More »On Health Policy
NCHR Testimony to the FDA on Transparency
June 24, 2009. I have scrutinized FDA policies, processes, and decisions as a Congressional investigator and in my current position.
Read More »NCHR Letter to U.S. Senator Charles Grassley (Ranking Member of the Finance Committee) supporting S. 301, the “Physician Payments Sunshine Act of 2009”
May 29, 2009. The Physician Payments Sunshine Act would bring much needed transparency to the often secretive financial relationships between medical products manufacturers and health care professionals.
Read More »NCHR Letter to U.S. Senator Dianne Feinstein (CA) supporting S. 925, the “Safe Baby Products Act of 2009”
May 19, 2009. On behalf of the National Research Center for Women & Families, I am writing to express our strong support for S. 925, the “Safe Baby Products Act of 2009,” which would examine cosmetics and personal care products marketed to children for impurities.
Read More »NCHR Letter to U.S. Sentor Kirsten Gillibrand (NY) Supporting the “Safe Baby Products Act of 2009”
May 19, 2009. On behalf of the National Research Center for Women & Families, I am writing to express our strong support for S. 925, the “Safe Baby Products Act of 2009,” which would examine cosmetics and personal care products marketed to children for impurities.
Read More »